Vir Biotechnology, Inc. (VIR) Stock Analysis and Metrics

Vir Biotechnology

NASDAQ: VIR

$8.69 ▼ -0.65 (-6.96%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap1.28 Bn

P/E-2.90

P/S19.60

Div. Yield0.00

Add ratio to table…

About

Vir Biotechnology, Inc. is a clinical stage biopharmaceutical company dedicated to harnessing the immune system to combat serious infectious diseases and cancer. The company discovers and develops therapeutic candidates that aim to enhance immune responses against viruses such as hepatitis delta and human immunodeficiency virus and to direct immune cells to destroy tumor cells in solid tumours. Its pipeline includes investigational antibody combinations for hepatitis delta and a series of masked T cell engagers targeting prostate, HER2 and EGFR expressing cancers. The firm relies on its internal antibody discovery engine and two core technology platforms to drive its research efforts.

Vir Biotechnology generates revenue primarily through collaboration and licensing agreements with pharmaceutical partners. These arrangements provide up front cash payments, equity investments and milestone payments tied to development, regulatory and sales achievements. The company also earns royalties on net sales of products that are commercialised by its partners. While it currently has no marketed products, future revenue will depend on the successful approval and sale of its pipeline candidates.

Vir Biotechnology occupies a niche in the biotechnology sector as a developer of immune modulating therapies that combine antibody engineering with proprietary masking technology. Its competitors in the hepatitis delta space include Gilead Sciences with its approved bulevirtide and other emerging firms pursuing alternative mechanisms. In oncology the company faces established players such as Roche, Johnson & Johnson and Novartis that are developing antibody drug conjugates and bispecific antibodies for similar tumour targets. Vir Biotechnology’s competitive edge stems from its dAIsY platform which uses artificial intelligence to optimise antibody properties and its exclusive licence to the PRO XTEN masking system that aims to improve the safety and potency of T cell engagers by limiting activity to the tumour microenvironment.

The company’s customers are primarily its collaboration partners which include Norgine for the hepatitis delta combination, Astellas for the prostate cancer T cell engager, GSK for Covid related antibodies and Alnylam for hepatitis B siRNA programs. These partners provide funding, share development costs and hold commercial rights in specific territories. In the future, should its products reach the market, the company will serve patients, healthcare providers and public health systems seeking treatments for serious viral infections and cancer.

Investment Thesis

▲ Bull case

Vir Biotechnology has secured a transformative collaboration with Astellas for VIR-5500, a PROXTEN dual-masked PSMA-targeted T cell engager for metastatic castration-resistant prostate cancer, which includes a $240 million upfront payment and potential for up to $1.37 billion in milestones plus double-digit royalties, providing substantial non-dilutive capital that de-risks near-term development while preserving significant long-term upside; the collaboration enables shared development costs (40% Vir, 60% Astellas) and 50/50 U.S. profit sharing, allowing Vir to advance VIR-5500 aggressively across the prostate cancer continuum without shouldering the full financial burden, and with Phase 3 initiation planned for 2027, the company is positioned to capture value from a best-in-class candidate showing deep and durable responses in heavily pre-treated mCRPC patients, including those with liver metastasis—a population historically resistant to immunotherapy—where Phase 1 data revealed sustained PSA and RECIST responses up to 27 weeks and emerging durability signals at 8 and 12 months, all with a favorable safety profile featuring no dose-limiting toxicities and predominantly Grade 1 cytokine release syndrome, supporting potential outpatient administration and broad clinical utility across pre- and post-radioligand therapy settings.
The hepatitis delta program is advancing toward multiple near-term catalysts with ECLIPSE 1 topline data expected in Q4 2026 and ECLIPSE 2 in Q1 2027, which together are viewed as sufficient to support a BLA filing for tobevibart plus elebsiran, a regimen demonstrating best-in-class efficacy in the Phase 2 SOLSTICE trial where 88% of evaluable participants achieved undetectable HDV RNA (target not detected) at Week 96 versus 46% on antibody monotherapy, with rapid onset of viral suppression (41% undetectable by Week 24) and no Grade 3 or higher treatment-related adverse events; the once-monthly subcutaneous dosing—a critical differentiator from competitors requiring daily or weekly injections—enables potential for both self-administration at home and physician administration in-office, addressing a key unmet need as up to 20% of patients may be unable to self-administer frequent regimens, and with FDA Breakthrough Therapy, Fast Track, EMA PRIME, and orphan designations already secured, the program benefits from regulatory engagement and confidence in achieving broad labels, especially given the significant underserved population of approximately 180,000 actively viremic patients across the U.S., UK, and EU, where underdiagnosis remains high (only 10–15% diagnosed in the U.S.), creating substantial launch upside if diagnostic pathways improve via reflex testing adoption.
Vir’s balance sheet reflects a strengthened financial position with $809.3 million in cash, cash equivalents, and investments as of March 31, 2026, which excludes the $315 million in proceeds from the Astellas collaboration closed April 15, 2026 (including $75 million equity investment and $240 million upfront payment), positioning the company to fund operations into the second half of 2028 per current operating plans, thereby de-risking near-term financing needs and enabling disciplined capital allocation across multiple value-creating milestones; this liquidity supports advancement of the preclinical T cell engager pipeline (seven additional PROXTEN-utilizing assets targeting solid tumors) and continued investment in oncology programs like VIR-5818 (HER2-targeted) and VIR-5525 (EGFR-targeted), which are progressing through Phase 1 with combination therapy signals expected in the second half of 2026, thereby broadening optionality and reducing reliance on any single program while leveraging the universal PROXTEN platform’s ability to translate learnings across indications and maintain a favorable therapeutic index through steric hindrance masking technology that avoids the need for target-specific redesigns.

Vir Biotechnology has secured a transformative collaboration with Astellas for VIR-5500, a PROXTEN dual-masked PSMA-targeted T cell engager for metastatic castration-resistant prostate cancer, which includes a $240 million upfront payment and potential for up to $1.37 billion in milestones plus double-digit royalties, providing substantial non-dilutive capital that de-risks near-term development while preserving significant long-term upside; the collaboration enables shared development costs (40% Vir, 60% Astellas) and 50/50 U.S. profit sharing, allowing Vir to advance VIR-5500 aggressively across the prostate cancer continuum without shouldering the full financial burden, and with Phase 3 initiation planned for 2027, the company is positioned to capture value from a best-in-class candidate showing deep and durable responses in heavily pre-treated mCRPC patients, including those with liver metastasis—a population historically resistant to immunotherapy—where Phase 1 data revealed sustained PSA and RECIST responses up to 27 weeks and emerging durability signals at 8 and 12 months, all with a favorable safety profile featuring no dose-limiting toxicities and predominantly Grade 1 cytokine release syndrome, supporting potential outpatient administration and broad clinical utility across pre- and post-radioligand therapy settings.
The hepatitis delta program is advancing toward multiple near-term catalysts with ECLIPSE 1 topline data expected in Q4 2026 and ECLIPSE 2 in Q1 2027, which together are viewed as sufficient to support a BLA filing for tobevibart plus elebsiran, a regimen demonstrating best-in-class efficacy in the Phase 2 SOLSTICE trial where 88% of evaluable participants achieved undetectable HDV RNA (target not detected) at Week 96 versus 46% on antibody monotherapy, with rapid onset of viral suppression (41% undetectable by Week 24) and no Grade 3 or higher treatment-related adverse events; the once-monthly subcutaneous dosing—a critical differentiator from competitors requiring daily or weekly injections—enables potential for both self-administration at home and physician administration in-office, addressing a key unmet need as up to 20% of patients may be unable to self-administer frequent regimens, and with FDA Breakthrough Therapy, Fast Track, EMA PRIME, and orphan designations already secured, the program benefits from regulatory engagement and confidence in achieving broad labels, especially given the significant underserved population of approximately 180,000 actively viremic patients across the U.S., UK, and EU, where underdiagnosis remains high (only 10–15% diagnosed in the U.S.), creating substantial launch upside if diagnostic pathways improve via reflex testing adoption.
Vir’s balance sheet reflects a strengthened financial position with $809.3 million in cash, cash equivalents, and investments as of March 31, 2026, which excludes the $315 million in proceeds from the Astellas collaboration closed April 15, 2026 (including $75 million equity investment and $240 million upfront payment), positioning the company to fund operations into the second half of 2028 per current operating plans, thereby de-risking near-term financing needs and enabling disciplined capital allocation across multiple value-creating milestones; this liquidity supports advancement of the preclinical T cell engager pipeline (seven additional PROXTEN-utilizing assets targeting solid tumors) and continued investment in oncology programs like VIR-5818 (HER2-targeted) and VIR-5525 (EGFR-targeted), which are progressing through Phase 1 with combination therapy signals expected in the second half of 2026, thereby broadening optionality and reducing reliance on any single program while leveraging the universal PROXTEN platform’s ability to translate learnings across indications and maintain a favorable therapeutic index through steric hindrance masking technology that avoids the need for target-specific redesigns.

▼ Bear case

Vir Biotechnology’s hepatitis delta program faces significant commercialization risks due to the highly underdiagnosed nature of chronic hepatitis delta, with only an estimated 10–15% of the approximately 61,000 actively viremic patients in the United States currently diagnosed and under physician care, meaning the addressable market at launch could be far smaller than the oft-cited 180,000 figure across the U.S., UK, and EU unless diagnostic pathways improve substantially; while reflex testing in Europe has increased diagnosis rates, no such guidelines are currently widespread in the U.S., and the current diagnostic algorithm—requiring sequential HBV, antibody, and RNA tests across multiple visits—creates a major barrier to identification, which could delay uptake even if ECLIPSE 1 and ECLIPSE 2 data are positive and support a BLA filing, as physicians may lack awareness or infrastructure to screen effectively, and payer reimbursement for diagnostics remains limited (Medicare reimbursement of ~$17 for antibody test and ~$43 for RNA test), potentially constraining market access despite favorable efficacy and convenience data.
The VIR-5500 collaboration with Astellas, while financially beneficial, introduces strategic dependencies and execution risks, as Vir has limited visibility into Astellas-led development activities post-Phase 1 despite joint governance committees, and any delays in Astellas’ internal processes, prioritization shifts, or disagreements over clinical development plans—particularly regarding trial design, dosing regimens, or combination strategies with enzalutamide in early-line mCRPC—could slow progress toward the anticipated 2027 Phase 3 initiation, especially given that Vir is relying on Astellas’ global leadership in prostate cancer to accelerate development, yet the company has not disclosed specific timelines for Astellas’ internal milestones or decision gates, creating uncertainty about whether the collaboration will truly expedite development as implied; furthermore, while PROXTEN masking technology is promoted as a platform advantage, the protease-cleavable linker’s broad activity across protease families may not translate consistently across tumor types, and differential cleavage kinetics in prostate versus colorectal or NSCLC—though not yet observed—could undermine the therapeutic index advantage if activation proves less tumor-specific than anticipated, particularly as Vir expands beyond VIR-5500 into earlier-line settings where safety margins are more critical.
Vir’s financial runway, while extended into the second half of 2028 per guidance, remains contingent on the successful execution of multiple high-stakes binary events, including positive outcomes from ECLIPSE 1 and ECLIPSE 2 (expected Q4 2026 and Q1 2027), initiation of VIR-5500 Phase 3 in 2027, and readouts from VIR-5818 and VIR-5525 in the second half of 2026, any failure of which could trigger renewed financing needs and erode investor confidence; the company continues to operate at a significant cash burn, with Q1 2026 R&D expenses of $108.9 million and SG&A of $23.3 million, and while the recent equity offering and Astellas proceeds have bolstered liquidity, the accumulated deficit stands at $1.32 billion as of March 31, 2026, reflecting persistent losses, and reliance on milestone payments and royalties from collaborations—some of which are shared with Sanofi (20% of certain Astellas proceeds)—means that even successful programs may not translate to proportional bottom-line benefits, especially if development costs exceed expectations or pricing pressure emerges in competitive markets like prostate cancer, where established agents such as Xtandi and radioligand therapies set high efficacy and tolerability benchmarks that VIR-5500 must surpass to gain meaningful market share.

Vir Biotechnology’s hepatitis delta program faces significant commercialization risks due to the highly underdiagnosed nature of chronic hepatitis delta, with only an estimated 10–15% of the approximately 61,000 actively viremic patients in the United States currently diagnosed and under physician care, meaning the addressable market at launch could be far smaller than the oft-cited 180,000 figure across the U.S., UK, and EU unless diagnostic pathways improve substantially; while reflex testing in Europe has increased diagnosis rates, no such guidelines are currently widespread in the U.S., and the current diagnostic algorithm—requiring sequential HBV, antibody, and RNA tests across multiple visits—creates a major barrier to identification, which could delay uptake even if ECLIPSE 1 and ECLIPSE 2 data are positive and support a BLA filing, as physicians may lack awareness or infrastructure to screen effectively, and payer reimbursement for diagnostics remains limited (Medicare reimbursement of ~$17 for antibody test and ~$43 for RNA test), potentially constraining market access despite favorable efficacy and convenience data.
The VIR-5500 collaboration with Astellas, while financially beneficial, introduces strategic dependencies and execution risks, as Vir has limited visibility into Astellas-led development activities post-Phase 1 despite joint governance committees, and any delays in Astellas’ internal processes, prioritization shifts, or disagreements over clinical development plans—particularly regarding trial design, dosing regimens, or combination strategies with enzalutamide in early-line mCRPC—could slow progress toward the anticipated 2027 Phase 3 initiation, especially given that Vir is relying on Astellas’ global leadership in prostate cancer to accelerate development, yet the company has not disclosed specific timelines for Astellas’ internal milestones or decision gates, creating uncertainty about whether the collaboration will truly expedite development as implied; furthermore, while PROXTEN masking technology is promoted as a platform advantage, the protease-cleavable linker’s broad activity across protease families may not translate consistently across tumor types, and differential cleavage kinetics in prostate versus colorectal or NSCLC—though not yet observed—could undermine the therapeutic index advantage if activation proves less tumor-specific than anticipated, particularly as Vir expands beyond VIR-5500 into earlier-line settings where safety margins are more critical.
Vir’s financial runway, while extended into the second half of 2028 per guidance, remains contingent on the successful execution of multiple high-stakes binary events, including positive outcomes from ECLIPSE 1 and ECLIPSE 2 (expected Q4 2026 and Q1 2027), initiation of VIR-5500 Phase 3 in 2027, and readouts from VIR-5818 and VIR-5525 in the second half of 2026, any failure of which could trigger renewed financing needs and erode investor confidence; the company continues to operate at a significant cash burn, with Q1 2026 R&D expenses of $108.9 million and SG&A of $23.3 million, and while the recent equity offering and Astellas proceeds have bolstered liquidity, the accumulated deficit stands at $1.32 billion as of March 31, 2026, reflecting persistent losses, and reliance on milestone payments and royalties from collaborations—some of which are shared with Sanofi (20% of certain Astellas proceeds)—means that even successful programs may not translate to proportional bottom-line benefits, especially if development costs exceed expectations or pricing pressure emerges in competitive markets like prostate cancer, where established agents such as Xtandi and radioligand therapies set high efficacy and tolerability benchmarks that VIR-5500 must surpass to gain meaningful market share.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password